Study guide

10.3 Hematologic & Neurologic Toxicity Management

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

10.3 Hematologic & Neurologic Toxicity Management

Key Takeaways Explain This Topic AI

Febrile neutropenia (FN) is a medical emergency defined as fever ( ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C single or ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C sustained 1 hour) with ANC < 500 / μ L <500/\mu\text{L} < 500/ μ L ; high-risk patients require immediate empiric IV antipseudomonal beta-lactam monotherapy.

Granulocyte colony-stimulating factors (G-CSF: filgrastim, pegfilgrastim) are indicated for primary FN prophylaxis when regimen risk is ≥ 20 % \ge 20\% ≥ 20% and must be administered 24-72 hours AFTER chemotherapy completion.

Erythropoiesis-stimulating agents (ESAs) are restricted by FDA REMS guidelines to non-curative palliative chemotherapy with hemoglobin < 10 g/dL <10\text{ g/dL} < 10 g/dL due to increased risks of mortality and tumor progression in curative settings.

Chemotherapy-induced peripheral neuropathy (CIPN) is caused by neurotoxic agents (oxaliplatin, taxanes, vincristine, bortezomib); ASCO guidelines recommend duloxetine as the only evidence-based treatment for painful CIPN.

Oxaliplatin causes a unique acute cold-induced dysesthesia of the pharyngolaryngeal tract and hands, requiring patient avoidance of cold liquids, cold air, and cold objects.

Last updated: August 2026

Hematologic & Neurologic Toxicity Management

Hematologic bone marrow suppression and neurological toxicities represent two major clinical challenges in cancer therapy. Myelosuppression exposes patients to life-threatening infectious and hemorrhagic risks, while neurotoxicity—particularly chemotherapy-induced peripheral neuropathy (CIPN)—can cause permanent functional disability. Advanced Practice Registered Nurses (APRNs) must rapidly recognize these toxicities, apply risk-stratified antibiotic and growth factor guidelines, and implement evidence-based neuroprotective interventions.

1. Febrile Neutropenia (FN) Assessment & Diagnostic Criteria

Febrile neutropenia (FN) is an oncologic emergency requiring immediate clinical evaluation and empiric antibiotic therapy within 60 minutes of presentation ("door-to-antibiotic" time) .

Clinical Definitions

Fever : A single oral temperature measurement of ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C ( 101.0 ∘ F 101.0^\circ\text{F} 101. 0 ∘ F ) , OR a sustained temperature of ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C ( 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ) lasting over a 1-hour period.

Neutropenia : An Absolute Neutrophil Count ( ANC ) of < 500 / μ L <500/\mu\text{L} < 500/ μ L , OR an ANC predicted to decline to < 500 / μ L <500/\mu\text{L} < 500/ μ L over the subsequent 48 hours. Absolute Neutrophil Count (ANC) = WBC × % Segmented Neutrophils + % Band Neutrophils 100 \text{Absolute Neutrophil Count (ANC)} = \text{WBC} \times \frac{\% \text{Segmented Neutrophils} + \% \text{Band Neutrophils}}{100} Absolute Neutrophil Count (ANC) = WBC × 100 % Segmented Neutrophils + % Band Neutrophils ​

Clinical Example : WBC = 1 , 200 / μ L 1,200/\mu\text{L} 1 , 200/ μ L , Segs = 20 % 20\% 20% , Bands = 5 % 5\% 5% . ANC = 1 , 200 × ( 0.20 + 0.05 ) = 300 / μ L \text{ANC} = 1,200 \times (0.20 + 0.05) = 300/\mu\text{L} ANC = 1 , 200 × ( 0.20 + 0.05 ) = 300/ μ L (Severe Neutropenia).

Diagnostic Workup

Immediate diagnostic evaluation must precede antibiotic administration (without delaying antibiotic delivery beyond 60 minutes):

Blood Cultures : Simultaneous draw of 2 sets of blood cultures (one peripheral set and one set from each lumen of central venous access devices).

Targeted Cultures : Urine culture, sputum culture, skin/wound drainage culture if clinically indicated.

Laboratory & Imaging : CBC with differential, Comprehensive Metabolic Panel (CMP), serum lactate, chest radiograph (to evaluate for pulmonary infiltrates).

2. Risk Stratification & Empirical Antibiotic Selection

Patients with FN are stratified into High-Risk or Low-Risk categories using validated tools such as the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index (score < 21 <21 < 21 indicates high risk; score ≥ 21 \ge 21 ≥ 21 indicates low risk) or the Clinical Index of Stable Febrile Neutropenia (CISNE).

Risk Category Clinical Criteria Recommended Antibiotic Regimen

High-Risk FN MASCC score < 21 <21 < 21 ; inpatient at fever onset; significant medical comorbidities (hypotension, organ dysfunction, severe mucositis); or profound neutropenia (ANC < 100 / μ L <100/\mu\text{L} < 100/ μ L ) expected to last > 7 >7 > 7 days. Immediate IV Monotherapy with an anti-pseudomonal β \beta β -lactam: Cefepime 2g IV Q8H , Piperacillin-Tazobactam 4.5g IV Q6H , or Meropenem 1g IV Q8H . Add IV Vancomycin only for specific indications (hemodynamic instability, catheter infection, skin/soft tissue infection, pneumonia, MRSA colonization).

Low-Risk FN MASCC score ≥ 21 \ge 21 ≥ 21 ; outpatient at fever onset; no severe comorbidities; brief neutropenia expected ( < 7 <7 < 7 days); stable hemodynamics. Oral Empirical Therapy (outpatient candidate with close follow-up): Ciprofloxacin 750 mg PO BID PLUS Amoxicillin-Clavulanate 875 mg PO BID (or Levofloxacin 750 mg PO daily monotherapy if penicillin allergic).

3. Myeloid Growth Factor Guidelines (G-CSF & GM-CSF)

Granulocyte Colony-Stimulating Factors ( G-CSFs : Filgrastim, Pegfilgrastim, tbo-filgrastim) stimulate neutrophil proliferation and differentiation.

ASCO / NCCN Indications for Primary Prophylaxis

Primary Prophylaxis : Recommended when the overall risk of febrile neutropenia for a given chemotherapy regimen is ≥ 20 % \ge 20\% ≥ 20% . Also indicated when FN risk is 10-20% if patient risk factors are present (age > 65 >65 > 65 , advanced disease, prior chemotherapy/radiation, persistent neutropenia, baseline cytopenias).

Secondary Prophylaxis : Indicated in patients who experienced a prior neutropenic complication in a previous cycle where dose reduction might compromise curative intent or overall survival.

Agents & Administration Timing Rules

Filgrastim : 5 μ g/kg/day 5\ \mu\text{g/kg/day} 5 μ g/kg/day SC daily, starting 24-72 hours post-chemotherapy, continued until post-nadir ANC recovery ( > 2 , 000 − 10 , 000 / μ L >2,000-10,000/\mu\text{L} > 2 , 000 − 10 , 000/ μ L ).

Pegfilgrastim : Single dose of 6 mg SC per chemotherapy cycle.

CRITICAL TIMING RULE : Pegfilgrastim/Filgrastim MUST BE ADMINISTERED 24 TO 72 HOURS AFTER COMPLETION OF CYTOTOXIC CHEMOTHERAPY . Administering G-CSF within 24 hours prior to or 24 hours after chemotherapy is strictly contraindicated because chemotherapy destroys rapidly proliferating myeloid progenitor cells stimulated by G-CSF, worsening bone marrow toxicity.

Adverse Effects : Bone pain (medullary expansion) occurring in 20-30% of patients. First-line APRN management: Loratadine 10 mg PO daily starting 1 day prior to G-CSF and continuing for 5-7 days, or short-course NSAIDs.

  • 4. Anemia Management & Erythropoiesis-Stimulating Agents (ESAs)
  • Platelet & RBC Transfusion Thresholds

Thrombocytopenia : Prophylactic platelet transfusion threshold is < 10 , 000 / μ L <10,000/\mu\text{L} < 10 , 000/ μ L in non-bleeding patients ( < 20 , 000 / μ L <20,000/\mu\text{L} < 20 , 000/ μ L in patients with active fever or high bleeding risk; < 50 , 000 / μ L <50,000/\mu\text{L} < 50 , 000/ μ L for minor procedures/active bleeding).

Anemia : Transfuse packed red blood cells (PRBCs) for hemoglobin < 7 − 8 g/dL <7-8\text{ g/dL} < 7 − 8 g/dL or symptomatic anemia.

ESA Safety Guidelines (Epoetin Alfa, Darbepoetin Alfa)

FDA REMS Requirements : ESAs are indicated ONLY for chemotherapy-induced anemia in patients with non-myeloid malignancies receiving CONCURRENT non-curative (palliative) chemotherapy with hemoglobin < 10 g/dL <10\text{ g/dL} < 10 g/dL .

Contraindications : Strictly contraindicated in patients receiving chemotherapy with CURATIVE INTENT . Large clinical trials demonstrate that ESAs shorten overall survival and increase time to tumor progression (tumor cell growth expression of erythropoietin receptors) as well as increasing arterial/venous thromboembolism (VTE) risks.

5. Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN results from structural axonopathy, neuronopathy, or microtubular damage caused by neurotoxic antineoplastic agents.

High-Risk Neurotoxic Agents & Clinical Features

Antineoplastic Class Common Agents Neurological Toxicity Presentation & APRN Clinical Nuances

Platinum Compounds Oxaliplatin, Cisplatin, Carboplatin Oxaliplatin : Causes two distinct toxicities: (1) Acute cold-induced dysesthesia (occurs during/within hours of infusion, causing pharyngolaryngeal dysesthesia, throat tightness, and distal paresthesias triggered by cold temperatures); (2) Chronic cumulative sensory neuropathy (stocking-glove sensory loss, ataxia). Cisplatin : Ototoxicity and sensory ataxia.

Taxanes Paclitaxel, Docetaxel, Nab-paclitaxel Sensory-predominant stocking-glove paresthesias, numbness, burning pain, motor weakness, lost deep tendon reflexes.

Vinca Alkaloids Vincristine, Vinblastine Peripheral motor/sensory neuropathy, drop foot, loss of DTRs. Autonomic neuropathy : Severe constipation, paralytic ileus, cranial nerve palsies, vocal cord paresis.

Proteasome Inhibitors Bortezomib Painful sensory paresthesias. Subcutaneous administration significantly reduces CIPN incidence compared to IV.

Evidence-Based CIPN Management Protocols

Prevention : No neuroprotective pharmacotherapy (glutamine, calcium/magnesium, vitamin B6, acetyl-L-carnitine) is recommended by ASCO guidelines for CIPN prevention.

Treatment of Established Painful CIPN : Duloxetine (SNRI) administered at 30 mg PO daily for 1 week, escalating to 60 mg PO daily , is the ONLY evidence-based agent recommended by ASCO guidelines demonstrating statistically significant efficacy in reducing painful CIPN.

Dose Modification : For Grade 2-3 functional motor impairment or painful sensory loss interfering with activities of daily living (ADLs), antineoplastic dose reduction, delay, or permanent discontinuation is required.

Neurotoxic Antineoplastic Agents & Relative Incidence of CIPN